News & Insights

This is where we share our own and our portfolio companies’ press releases as well as relevant Sunstone articles, analyses and SoMe posts.

5 latest press releases

Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients’ cytotoxic T-cells targeting a wide range of cancer-related...

TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients

TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today announces it has raised Series A financing of EUR 39 million to accelerate development of its lead compound, Microlyse. The...

MinervaX Provides Clinical Update on its Maternal GBS Vaccine

MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces significant clinical progress on its maternal GBS vaccine.     Press inquiries should be adressed to:    

Sunstone Life Science Ventures is looking for a Student Assistant

No longer accepting applications We are looking for a student to join our team for approximately 8 hours a week. As part of the team, you will play a pivotal role in the management of our deal flow, which lies in the order of 400-500 opportunities every year....

5 latest articles

Who is in the driver’s seat of our industry?

A recent analysis from Pharma Intelligence | Informa 2021 highlights the current trends of pipeline products (top panel). We have subsequently surveyed Sunstone’s incoming deal flow for the same period and noted the correlation for the top 3 categories with oncology...

US IPO: Value recognition? Not really! Trading liquidity? Yes!

We previously looked at M&A of VC funded private and listed companies in the EU and US (https://bit.ly/3EU4n8H). Listing EU companies in the US is perceived as more attractive or beneficial – but is it reflected in the numbers?  Recently, we decided to take a...

Why would you do a US IPO?

We recently compared EUR >50M M&A’s of VC funded EU and US drug developing companies and concluded that a substantial difference exists between the EU and US (https://bit.ly/3uftQmU). Previously we have also looked at EU M&A’s before or after an IPO....

M&A multiples in the US – should you go west?

Sunstone has previously investigated the return multiples of venture capital funded companies HQ’ed in Europe (https://bit.ly/3n0bd3B) and concluded that when the total invested amount exceeds EUR 50M, the return multiple tends to stay below 5 in M&A transactions....

Best country for sourcing new deals?

Do you also in your mind have a priority list of destinations to visit once the world normalises and you can get back on a plane? If so, and if you are a Venture Capitalist, you may also be wondering which countries have been creating most Life Science M&A...

Why are we investing in Drug Development and hesitating with regards to Medical Devices or Diagnostics?

Part of the answer is obviously that our past experiences and successes fall within Drug Development – but also that both MedTech and Diagnostics seem to have a lower likelihood of getting to an exit once you have invested. Defining the field for Medical Devices and...

News Archive

Kim Stratton, CEO, resigns from Orphazyme

Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton has decided to resign from Orphazyme following a...

Arimoclomol has been granted FDA Fast Track and Breakthrough Therapy Designations for NPC, as well as Orphan Drug and Rare Pediatric Disease Designations. Orphazyme expects to file an MAA with the EMA for arimoclomol in NPC in H2 2020.

Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the...

Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe

Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that it has filed a registration statement on Form F-1 with the U.S....

Articles Archive

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Or follow us on LinkedIn